ICON announced that its Medical Imaging division has made MIRA™, ICON’s medical image review and analysis software, available to clients in an Application Service Provider (ASP) model. ICON Medical Imaging is the first medical imaging provider to offer clients an ASP solution for their image management needs.
MIRA™ is the core application used by ICON Medical Imaging in its daily operations and provides functionality for imaging, image analysis, project management and document management for imaging studies. MIRA™ is also used for central image evaluations and clinical endpoint committees.
With an ASP model, clients can use MIRA™ as a central repository for medical images and have secure, online access to their imaging data anytime, anywhere. The new model also eliminates the costs associated with purchasing and maintaining an image management system in-house and provides a broad platform upon which clients can build their intellectual property framework, including integration with a clinical data repository for a comprehensive view of all clinical trial data components.
The MIRA™ ASP solution offers turn-key cloud hosting services. Each customer is provided with a private cloud, thereby addressing FDA considerations associated with distributed data stores. As the core operational system for ICON Medical Imaging, MIRA™ meets associated industry guidelines and has passed every client and FDA study audit since its first release in 2005.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Truqap Combination Shines in Phase III Trial for Prostate Cancer
November 26th 2024Data from the CAPItello-281 trial show Truqap alongside abiraterone and androgen deprivation therapy achieved a statistically significant and clinically meaningful improvement in radiographic progression-free survival.
Empowering Sites and Patients: The Impact of Personalized Support in Clinical Trials
November 26th 2024To meet the growing demands of clinical research, sponsors must prioritize comprehensive support models, such as clinical site ambassadors and patient journey coordinators, who can address operational challenges and improve site relationships, patient satisfaction, and overall trial efficiency.